Default company panoramic image
Logo

NanCogenics Inc

NanCogenics, in collaboration with a major cancer institute, has validated a platform for tumor-specific localization of cancer therapeutics

  • Stage Product In Development
  • Industry Nanotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Founded August 2012
  • Employees 3
  • Website nancogenics.com

Company Summary

NanCogenics, a privately held Corporation, has developed and validated a proprietary technology platform for the tumor-specific localization of cancer therapeutics, with initial business focus on establishing a clinical procedure for the treatment of breast cancers. One in eight women are projected to be diagnosed with breast cancer, and a significant majority will opt to undergo systemic chemotherapy, in spite of dose limiting side effects.

Team

  • Default avatar
    Jim Klostergaard
    Co-Founder

    Jim Klostergaard (Ph.D.) has been at the UT MD Anderson Cancer Center for over 30 years and currently holds the position of Professor of Molecular and Cellular Oncology. He was a Co-Founder of the first start-up business to emerge from MD Anderson and his research in areas of the biology of breast cancers has appeared in 110 publications in peer-reviewed journals and he currently holds four US Patents.

  • Default avatar
    Charles Seeney
    Co-Founder

    Charles Seeney (MS) is a scientist/entrepreneur in the area of nanobiotechnology deployment. He was Founder/Managing Director of ViCorp Tech, a firm involved in techno-business ventures., serving as CEO of several start-ups. NCGI is the 6th start-up under his direction, and his 4th in nanotechnology. The IP of two ventures was acquired by global organizations. He holds 21 US Patents and has been published in peer-reviewed journals.

  • Default avatar
    Judith Campbell-Washington
    Chief Science Officer

    Judith Campbell-Washington (PhD) will be the CSO for the Company. From 2007-2012, Dr. Campbell-Washington held the position of Director of Applied Sciences for The Bionetics Corporation, a diversified engineering and applied science organization, where she was responsible for the strategic planning and corporate executive management of the Applied Sciences Group programs for multiple government contracts with the FDA, EPA, NIH and DOD.

  • Default avatar
    Martin von Dyck
    Chief Executive Officer

    Martin von Dyck will be the Chief Executive Officer for the Company. Since 2000, Mr. von Dyck has been the Executive Vice President for Biosearch Medical Products, Inc., responsible for the strategic corporate alignment of the firm’s product lines, intellectual property, licensing, royalty revenues, vendor agreements and distributor relationships. Mr. von Dyck is also accountable for all marketing and sales initiatives and profits objectives.

  • Default avatar
    Gregory Guidroz
    Chief Financial Officer

    Greg Guidroz (CPA) will be the Chief Financial Officer for the Company. From 2009 to present, Mr. Guidroz has provided financial consulting services for various start-up corporations. His clients have included early stage medical device and scientific equipment firms and a trade association organization. From 2007-2009, Mr. Guidroz was the Chief Financial Officer for a venture capital-backed manufacturer of optical components.

  • Default avatar
    Christoph Alexiou
    Science Advisory Board

    Christoph Alexiou (MD) will be a Member of the Science Advisory Board. He is a physician and researcher with knowledge in areas of nanotechnology and magnetic nanoparticles as it relates to the treatment of cancer Since 2009, Dr. Alexiou has been a Professor of Nanomedicine and Head of the Section for Experimental Oncology and Nanomedicine for W3 Else Kroner- Fresenius-Stiftung, which is one of the largest private foundations in Germany.

  • Default avatar
    Joan Bull
    Science Advisory Board

    Dr. Joan Bull (MD) will be a Member of the Science Advisory Board. She is an experienced medical oncologist, with particular emphasis in breast, lung and gastrointestinal malignancies and has spent over three decades in the research of cancer. Presently, Dr. Bull is a full Professor and has been Director of the Division of Oncology at the University of Texas Medical School, as well as a Director of the Oncology Clinic at Hermann Hospital.